SOLV Stock Analysis — Solventum
Sector: Healthcare
AI Verdict
SOLV trades at 10.9x next year's earnings but with EPS expected to fall -26.3%, so while it's cheap on the numbers, the defensibility of its hospital supply contracts will be tested if profitability keeps sliding.
Competitive Moat
Solventum manufactures specialized healthcare products and consumables, benefiting from long-term hospital supply contracts and regulatory hurdles that make switching suppliers costly and risky. Their defensibility comes from embedded relationships with healthcare providers and compliance-driven barriers to entry.
Summary
Solventum trades at just 10.9x forward earnings, but analysts expect a steep -26.3% drop in EPS next year.
Where It Stands
SOLV has delivered a 7.53% one-year return, sits at a neutral RSI of 56.2, and trades at a deep discount to the healthcare sector's 22x median forward P/E.
Key Metrics
- RSI: 56.2 — Neutral
- Trailing P/E: 8.1x
- Forward P/E: 10.9x
- Earnings Growth: -0.3%
- Revenue Growth: +0.0%
- Market Cap: $12.4B
- 1-Year Return: 7.53%
- 52-Week High: $88.20
- 52-Week Low: $62.38
Analyst Consensus
11 Buy · 8 Hold · 2 Sell (21 analysts)
Bull Case
With a trailing P/E of 8.1x, the stock is priced well below sector peers, suggesting the market is already discounting weak near-term results.
Bear Case
If the forward P/E of 10.9x holds while EPS drops -26.3%, any further multiple compression could erase this year's 7.53% gain and more.
Catalyst to Watch
Watch for quarterly earnings updates—any sign that the EPS decline moderates from -26.3% consensus could trigger a rerating.